{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:03:49Z","timestamp":1770678229907,"version":"3.49.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/ncprheum0042","type":"journal-article","created":{"date-parts":[[2006,5,17]],"date-time":"2006-05-17T15:06:41Z","timestamp":1147878401000},"page":"20-27","source":"Crossref","is-referenced-by-count":85,"title":["B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus"],"prefix":"10.1038","volume":"2","author":[{"given":"Robert","family":"Eisenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncprheum0042_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/eji.200425888","volume":"35","author":"R Eisenberg","year":"2005","unstructured":"Eisenberg R (2005) Do autoantigens define autoimmunity or vice versa? Eur J Immunol 35: 367\u2013370","journal-title":"Eur J Immunol"},{"key":"BFncprheum0042_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/0966-842X(96)10059-7","volume":"4","author":"MK Slifka","year":"1996","unstructured":"Slifka MK and Ahmed R (1996) Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol 4: 394\u2013400","journal-title":"Trends Microbiol"},{"issue":"Suppl 3","key":"BFncprheum0042_CR3","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1186\/ar1738","volume":"7","author":"E Keystone","year":"2005","unstructured":"Keystone E (2005) B cell targeted therapies. Arthritis Res Ther 7 (Suppl 3): S13\u2013S18","journal-title":"Arthritis Res Ther"},{"key":"BFncprheum0042_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20042251","volume":"201","author":"S Yurasov","year":"2005","unstructured":"Yurasov S et al. (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201: 703\u2013711","journal-title":"J Exp Med"},{"key":"BFncprheum0042_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20042321","volume":"201","author":"J Samuels","year":"2005","unstructured":"Samuels J et al. (2005) Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 201: 1659\u20131667","journal-title":"J Exp Med"},{"key":"BFncprheum0042_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1073\/pnas.93.1.221","volume":"93","author":"AE Schroder","year":"1996","unstructured":"Schroder AE et al. (1996) Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 93: 221\u2013225","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0042_CR7","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura S et al. (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167: 4710\u20134718","journal-title":"J Immunol"},{"key":"BFncprheum0042_CR8","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl M et al. (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165: 5970\u20135979","journal-title":"J Immunol"},{"key":"BFncprheum0042_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/096120339600500314","volume":"5","author":"A Swaak","year":"1996","unstructured":"Swaak A and van den Brink HG (1996) Case report: common variable immunodeficiency in a patient with systemic lupus erythematosus. Lupus 5: 242\u2013246","journal-title":"Lupus"},{"key":"BFncprheum0042_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1006\/smim.1994.1008","volume":"6","author":"RA Eisenberg","year":"1994","unstructured":"Eisenberg RA et al. (1994) The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice. Semin Immunol 6: 49\u201354","journal-title":"Semin Immunol"},{"key":"BFncprheum0042_CR11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","volume":"189","author":"OT Chan","year":"1999","unstructured":"Chan OT et al. (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189: 1639\u20131648","journal-title":"J Exp Med"},{"key":"BFncprheum0042_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ni0901-764","volume":"2","author":"PE Lipsky","year":"2001","unstructured":"Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2: 764\u2013766","journal-title":"Nat Immunol"},{"issue":"Suppl 14","key":"BFncprheum0042_CR13","first-page":"66","volume":"26","author":"AJ Grillo-L\u00f3pez","year":"1999","unstructured":"Grillo-L\u00f3pez AJ et al. (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 (Suppl 14): 66\u201373","journal-title":"Semin Oncol"},{"key":"BFncprheum0042_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder TF and Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450\u2013454","journal-title":"Immunol Today"},{"key":"BFncprheum0042_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s002510050412","volume":"48","author":"TL O'Keefe","year":"1998","unstructured":"O'Keefe TL et al. (1998) Mice carrying a CD20 gene disruption. Immunogenetics 48: 125\u2013132","journal-title":"Immunogenetics"},{"key":"BFncprheum0042_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ et al. (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61: 883\u2013888","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0042_CR17","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ et al. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673\u20132677","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood.V98.4.952","volume":"98","author":"R Stasi","year":"2001","unstructured":"Stasi R et al. (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98: 952\u2013957","journal-title":"Blood"},{"key":"BFncprheum0042_CR19","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","volume":"52","author":"TD Levine","year":"1999","unstructured":"Levine TD and Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52: 1701\u20131704","journal-title":"Neurology"},{"key":"BFncprheum0042_CR20","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","volume":"44","author":"U Specks","year":"2001","unstructured":"Specks U et al. (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836\u20132840","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR21","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827\u20133834","journal-title":"Blood"},{"key":"BFncprheum0042_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52: 601\u2013607","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR23","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","volume":"101","author":"M Zecca","year":"2003","unstructured":"Zecca M et al. (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101: 3857\u20133861","journal-title":"Blood"},{"key":"BFncprheum0042_CR24","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572\u20132581","journal-title":"N Engl J Med"},{"key":"BFncprheum0042_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards JC and Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40: 205\u2013211","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl III","key":"BFncprheum0042_CR26","first-page":"58","volume":"64","author":"P Emery","year":"2005","unstructured":"Emery P et al. (2005) Primary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER trial) [abstract]. Ann Rheum Dis 64 (Suppl III): 58","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0042_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11926-003-0020-x","volume":"5","author":"J Anolik","year":"2003","unstructured":"Anolik J et al. (2003) B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 5: 350\u2013356","journal-title":"Curr Rheumatol Rep"},{"key":"BFncprheum0042_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52: 501\u2013513","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0042_CR30","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/03009740410010227","volume":"33","author":"RF van Vollenhoven","year":"2004","unstructured":"van Vollenhoven RF et al. (2004) Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33: 423\u2013427","journal-title":"Scand J Rheumatol"},{"key":"BFncprheum0042_CR32","first-page":"787","volume":"22","author":"DJ Armstrong","year":"2004","unstructured":"Armstrong DJ et al. (2004) Active systemic lupus erythematosus successfully treated with rituximab and oral steroid. Clin Exp Rheumatol 22: 787\u2013788","journal-title":"Clin Exp Rheumatol"},{"key":"BFncprheum0042_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH et al. (2003) The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455\u2013459","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR34","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580\u20133590","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"BFncprheum0042_CR35","first-page":"S740","volume":"52","author":"J Dunham","year":"2005","unstructured":"Dunham J et al. (2005) A longitudinal analysis of SLE patients treated with rituximab: a comparison of B cell depleters to partial B cell depleters [abstract]. Arthritis Rheum 52 (Suppl 9): S740","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR36","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793\u20131800","journal-title":"Blood"},{"key":"BFncprheum0042_CR37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.leu.2401779","volume":"14","author":"L Herrera","year":"2000","unstructured":"Herrera L et al. (2000) Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14: 853\u2013858","journal-title":"Leukemia"},{"key":"BFncprheum0042_CR38","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","volume":"10","author":"JP Leonard","year":"2004","unstructured":"Leonard JP et al. (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results. Clin Cancer Res 10: 5327\u20135334","journal-title":"Clin Cancer Res"},{"key":"BFncprheum0042_CR39","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907\u20131915","journal-title":"N Engl J Med"},{"key":"BFncprheum0042_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1191\/0961203304lu1032oa","volume":"13","author":"PI Sidiropoulos","year":"2004","unstructured":"Sidiropoulos PI and Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391\u2013397","journal-title":"Lupus"},{"key":"BFncprheum0042_CR41","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.4049\/jimmunol.173.9.5880","volume":"173","author":"KM Pollard","year":"2004","unstructured":"Pollard KM et al. (2004) Costimulation requirements of induced murine systemic autoimmune disease. J Immunol 173: 5880\u20135887","journal-title":"J Immunol"},{"key":"BFncprheum0042_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000082108","volume":"8","author":"W Stohl","year":"2005","unstructured":"Stohl W (2005) BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 8: 289\u2013304","journal-title":"Curr Dir Autoimmun"},{"key":"BFncprheum0042_CR43","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761\u20131769","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1191\/0961203304lu1023oa","volume":"13","author":"E Tackey","year":"2004","unstructured":"Tackey E et al. (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13: 339\u2013343","journal-title":"Lupus"},{"key":"BFncprheum0042_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0896-8411(03)00043-X","volume":"20","author":"L Llorente","year":"2003","unstructured":"Llorente L and Richaud-Patin Y (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20: 287\u2013289","journal-title":"J Autoimmun"},{"key":"BFncprheum0042_CR46","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.20980","volume":"52","author":"MD Linnik","year":"2005","unstructured":"Linnik MD et al. (2005) Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52: 1129\u20131137","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR47","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1126\/science.1105160","volume":"307","author":"TL McGaha","year":"2005","unstructured":"McGaha TL et al. (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307: 590\u2013593","journal-title":"Science"},{"key":"BFncprheum0042_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1023\/A:1025534223168","volume":"8","author":"T Mizuno","year":"2003","unstructured":"Mizuno T et al. (2003) Fas-induced apoptosis in B cells. Apoptosis 8: 451\u2013460","journal-title":"Apoptosis"},{"issue":"Suppl 2","key":"BFncprheum0042_CR49","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.028282","volume":"63","author":"RH Carter","year":"2004","unstructured":"Carter RH (2004) B cell signalling as therapeutic target. Ann Rheum Dis 63 (Suppl 2): ii65\u2013ii66","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0042_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000082101","volume":"8","author":"G Jego","year":"2005","unstructured":"Jego G et al. (2005) Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 8: 124\u2013139","journal-title":"Curr Dir Autoimmun"},{"key":"BFncprheum0042_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000082086","volume":"8","author":"FE Lund","year":"2005","unstructured":"Lund FE et al. (2005) Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 8: 25\u201354","journal-title":"Curr Dir Autoimmun"},{"key":"BFncprheum0042_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nrd914","volume":"1","author":"C Zuany-Amorim","year":"2002","unstructured":"Zuany-Amorim C et al. (2002) Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 1: 797\u2013807","journal-title":"Nat Rev Drug Discov"},{"key":"BFncprheum0042_CR53","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1002\/art.20519","volume":"50","author":"A Hutloff","year":"2004","unstructured":"Hutloff A et al. (2004) Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 50: 3211\u20133220","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR54","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.1073\/pnas.89.18.8522","volume":"89","author":"T Nakamura","year":"1992","unstructured":"Nakamura T et al. (1992) Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci USA 89: 8522\u20138526","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0042_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1034\/j.1600-065X.2003.00041.x","volume":"194","author":"JG Cyster","year":"2003","unstructured":"Cyster JG (2003) Homing of antibody secreting cells. Immunol Rev 194: 48\u201360","journal-title":"Immunol Rev"},{"key":"BFncprheum0042_CR56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.0019-2805.2004.01838.x","volume":"111","author":"G Borland","year":"2004","unstructured":"Borland G and Cushley W (2004) Positioning the immune system: unexpected roles for \u03b16-integrins. Immunology 111: 381\u2013383","journal-title":"Immunology"},{"key":"BFncprheum0042_CR57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nri1203","volume":"3","author":"EJ Kunkel","year":"2003","unstructured":"Kunkel EJ and Butcher EC (2003) Plasma-cell homing. Nat Rev Immunol 3: 822\u2013829","journal-title":"Nat Rev Immunol"},{"key":"BFncprheum0042_CR58","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/A:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K et al. (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Annals of Oncology 9: 527\u2013534","journal-title":"Annals of Oncology"},{"key":"BFncprheum0042_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000082103","volume":"8","author":"JC Edwards","year":"2005","unstructured":"Edwards JC et al. (2005) B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 8: 175\u2013192","journal-title":"Curr Dir Autoimmun"},{"key":"BFncprheum0042_CR60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/rheumatology\/keh446","volume":"44","author":"JC Edwards","year":"2005","unstructured":"Edwards JC and Cambridge G (2005) Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44: 151\u2013156","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0042_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","volume":"5","author":"CM Bearden","year":"2005","unstructured":"Bearden CM et al. (2005) Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 5: 50\u201357","journal-title":"Am J Transplant"},{"key":"BFncprheum0042_CR62","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMc055235","volume":"353","author":"BA Adelman","year":"2005","unstructured":"Adelman BA et al. (2005) Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 353: 432\u2013433","journal-title":"N Engl J Med"},{"key":"BFncprheum0042_CR63","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","volume":"44","author":"CA D'Arcy","year":"2001","unstructured":"D'Arcy CA and Mannik M (2001) Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 44: 1717\u20131718","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0042_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","volume":"44","author":"H Tahir","year":"2005","unstructured":"Tahir H et al. (2005) Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44: 561\u2013562","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0042_CR65","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong Q et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174: 817\u2013826","journal-title":"J Immunol"},{"key":"BFncprheum0042_CR66","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","volume":"358","author":"P Quartier","year":"2001","unstructured":"Quartier P et al. (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358: 1511\u20131513","journal-title":"Lancet"},{"key":"BFncprheum0042_CR67","unstructured":"Quartier P et al. (online 16 January 2003) Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. [ Link to original article ] (accessed 30 September 2005)"},{"key":"BFncprheum0042_CR68","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg MS et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140\u2013174","journal-title":"Curr Dir Autoimmun"},{"key":"BFncprheum0042_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","volume":"107","author":"JP Deans","year":"2002","unstructured":"Deans JP et al. (2002) CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107: 176\u2013182","journal-title":"Immunology"},{"key":"BFncprheum0042_CR70","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","volume":"104","author":"C Bezombes","year":"2004","unstructured":"Bezombes C et al. (2004) Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166\u20131173","journal-title":"Blood"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0042","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:22:54Z","timestamp":1736382174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BFncprheum0042"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0042","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}